Prosight Management LP Acquires 619,891 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Prosight Management LP grew its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 87.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,325,000 shares of the company's stock after acquiring an additional 619,891 shares during the quarter. Kura Oncology comprises approximately 3.2% of Prosight Management LP's portfolio, making the stock its 14th biggest position. Prosight Management LP owned approximately 1.70% of Kura Oncology worth $11,541,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of KURA. Barclays PLC raised its position in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Kura Oncology during the 4th quarter valued at about $436,000. Moody Aldrich Partners LLC lifted its holdings in Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after buying an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in Kura Oncology during the 4th quarter valued at $623,000.

Kura Oncology Stock Up 0.2%

Shares of KURA stock traded up $0.01 on Tuesday, hitting $6.25. 357,730 shares of the stock were exchanged, compared to its average volume of 1,177,089. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $6.39 and a 200 day moving average of $8.65. The firm has a market capitalization of $541.09 million, a P/E ratio of -2.65 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. Equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on KURA shares. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. StockNews.com downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, Mizuho dropped their price objective on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $24.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.